December 1, 2023
Integrase Inhibitors Market

The Integrase Inhibitors Market Is Estimated To Witness High Growth Owing To Rising Trend Of Drug Resistant HIV

The Integrase Inhibitors Market is estimated to be valued at US$ 29.34 Bn in 2023 and is expected to exhibit a CAGR of 3.9% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Integrase inhibitors are a class of antiviral drugs used primarily in highly active antiretroviral therapy (HAART) for treatment of HIV infection and AIDS. These drugs inhibit HIV integrase, an enzyme required for HIV replication. They have advantages such as high efficacy and less side effects compared to other antiretroviral drugs. Integrase inhibitors play a vital role in providing effective treatment options for HIV patients.

Market key trends:

The integrase inhibitors market is primarily driven by increasing prevalence of HIV/AIDS globally. According to UNAIDS, around 38 million people were living with HIV globally in 2019. Further, growing resistance to other classes of antiretroviral drugs is also contributing to the growth of integrase inhibitors market. Additionally, increasing awareness about HIV treatment and supportive government initiatives are fueling the market growth. Moreover, ongoing research and pipeline drugs with improved efficacy and tolerability are expected to present lucrative growth opportunities for integrase inhibitors market over the forecast period.

Porter’s Analysis
Threat of new entrants: The high costs of R&D and clinical trials required to develop new integrase inhibitors pose significant entry barriers.
Bargaining power of buyers: Large buyers like governments and hospitals can negotiate lower prices from established manufacturers due to their high purchase volumes.
Bargaining power of suppliers: A few global pharmaceutical companies dominate the supply of integrase inhibitor APIs, allowing them stronger bargaining power.
Threat of new substitutes: New drug classes like HIV maturation inhibitors are being developed but currently no substitutes exists with comparable efficacy.
Competitive rivalry: Key players compete through continuous innovation to develop new fixed-dose combinations and long-acting formulations.

SWOT Analysis
Strength: Existing drugs have demonstrated high effectiveness against drug-resistant HIV strains. Weakness: High costs associated with R&D and commercialization of new drugs limits market access in low-income regions.
Opportunity: Rising global HIV incidence, especially in Africa and Asia, indicates future market potential. Diversification into newer drug classes also presents opportunities.
Threats: Generic competition post patent expiry of leading brands pose pricing challenges. Stringent regulatory norms for approvals further delay market entry of new players.

Key Takeaways
Global Integrase Inhibitors Market Size is expected to witness high growth, exhibiting CAGR of 3.9% over the forecast period, due to increasing prevalence of HIV infections worldwide. North America currently dominates the market due to high treatment uptake though Asia Pacific is projected to witness fastest gains owing to large patient pools and improving access to therapy in middle-income countries.

Regional analysis: Asia Pacific region is projected to witness fastest growth in the integrase inhibitors market over the forecast period. This is attributed to the large HIV patient base, especially in India and China along with improving healthcare access and infrastructure.

Key players: Key players operating in the integrase inhibitors market incorporate Gilead Sciences, ViiV Healthcare, Merck & Co., Inc., GlaxoSmithKline PLC, Bristol-Myers Squibb Company, Johnson & Johnson, AbbVie Inc., Janssen, Pharmaceuticals, Inc., Theratechnologies Inc., Shionogi & Co., Ltd. These companies are focusing on new product launches and approvals to consolidate their market positions.

1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it